دورية أكاديمية
Prediction of O(6)-methylguanine-DNA methyltransferase promoter methylation status in IDH-wildtype glioblastoma using MRI histogram analysis.
| العنوان: | Prediction of O(6)-methylguanine-DNA methyltransferase promoter methylation status in IDH-wildtype glioblastoma using MRI histogram analysis. |
|---|---|
| المؤلفون: | Liu X; Department of Radiology, Lanzhou University Second Hospital, Cuiyingmen No.82, Chengguan District, Lanzhou, 730030, People's Republic of China.; Gansu International Scientific and Technological Cooperation Base of Medical Imaging Artificial Intelligence, Lanzhou, People's Republic of China.; Key Laboratory of Medical Imaging of Gansu Province, Lanzhou, People's Republic of China., Han T; Department of Radiology, Lanzhou University Second Hospital, Cuiyingmen No.82, Chengguan District, Lanzhou, 730030, People's Republic of China.; Gansu International Scientific and Technological Cooperation Base of Medical Imaging Artificial Intelligence, Lanzhou, People's Republic of China.; Key Laboratory of Medical Imaging of Gansu Province, Lanzhou, People's Republic of China., Wang Y; Key Laboratory of Medical Imaging of Gansu Province, Lanzhou, People's Republic of China.; Department of nuclear medicine, Gansu Provincial Cancer Hospital, No.2 East Xiaoxihu Street, Qilihe District, Lanzhou, 730050, People's Republic of China.; Department of nuclear medicine, Sun Yat-sen University Cancer Center Gansu Hospital, No.2 East Xiaoxihu Street, Qilihe District, Lanzhou, 730050, People's Republic of China., Liu H; Department of Radiology, Lanzhou University Second Hospital, Cuiyingmen No.82, Chengguan District, Lanzhou, 730030, People's Republic of China.; Gansu International Scientific and Technological Cooperation Base of Medical Imaging Artificial Intelligence, Lanzhou, People's Republic of China.; Key Laboratory of Medical Imaging of Gansu Province, Lanzhou, People's Republic of China., Zhou J; Department of Radiology, Lanzhou University Second Hospital, Cuiyingmen No.82, Chengguan District, Lanzhou, 730030, People's Republic of China. lzuzhoujl601@163.com.; Gansu International Scientific and Technological Cooperation Base of Medical Imaging Artificial Intelligence, Lanzhou, People's Republic of China. lzuzhoujl601@163.com.; Key Laboratory of Medical Imaging of Gansu Province, Lanzhou, People's Republic of China. lzuzhoujl601@163.com. |
| المصدر: | Neurosurgical review [Neurosurg Rev] 2024 Jun 22; Vol. 47 (1), pp. 285. Date of Electronic Publication: 2024 Jun 22. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Berlin Heidelberg Country of Publication: Germany NLM ID: 7908181 Publication Model: Electronic Cited Medium: Internet ISSN: 1437-2320 (Electronic) Linking ISSN: 03445607 NLM ISO Abbreviation: Neurosurg Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Berlin : Springer Berlin Heidelberg Original Publication: Berlin : Walter De Gruyter |
| مواضيع طبية MeSH: | Glioblastoma*/genetics , Glioblastoma*/diagnostic imaging , Glioblastoma*/pathology , Magnetic Resonance Imaging*/methods , Brain Neoplasms*/genetics , Brain Neoplasms*/diagnostic imaging , Brain Neoplasms*/pathology , Promoter Regions, Genetic*/genetics , DNA Methylation*/genetics , Isocitrate Dehydrogenase*/genetics, Humans ; Male ; Female ; Middle Aged ; Adult ; Aged ; Retrospective Studies ; O(6)-Methylguanine-DNA Methyltransferase/genetics |
| مستخلص: | To evaluate the utility of magnetic resonance imaging (MRI) histogram parameters in predicting O(6)-methylguanine-DNA methyltransferase promoter (pMGMT) methylation status in IDH-wildtype glioblastoma (GBM). From November 2021 to July 2023, forty-six IDH-wildtype GBM patients with known pMGMT methylation status (25 unmethylated and 21 methylated) were enrolled in this retrospective study. Conventional MRI signs (including location, across the midline, margin, necrosis/cystic changes, hemorrhage, and enhancement pattern) were assessed and recorded. Histogram parameters were extracted and calculated by Firevoxel software based on contrast-enhanced T1-weighted images (CET1). Differences and diagnostic performance of conventional MRI signs and histogram parameters between the pMGMT-unmethylated and pMGMT-methylated groups were analyzed and compared. No differences were observed in the conventional MRI signs between pMGMT-unmethylated and pMGMT-methylated groups (all p > 0.05). Compared with the pMGMT-methylated group, pMGMT-unmethylated showed a higher minimum, mean, Perc.01, Perc.05, Perc.10, Perc.25, Perc.50, and coefficient of variation (CV) (all p < 0.05). Among all significant CET1 histogram parameters, minimum achieved the best distinguishing performance, with an area under the curve of 0.836. CET1 histogram parameters could provide additional value in predicting pMGMT methylation status in patients with IDH-wildtype GBM, with minimum being the most promising parameter. (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.) |
| References: | Chen X, Zhang M, Gan H, Wang H, Lee JH, Fang D, Kitange GJ, He L, Hu Z, Parney IF, Meyer FB, Giannini C, Sarkaria JN, Zhang Z (2018) A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 9(1):2949. https://doi.org/10.1038/s41467-018-05373-4. (PMID: 10.1038/s41467-018-05373-4300544766063898) Choi YS, Ahn SS, Kim DW, Chang JH, Kang SG, Kim EH, Kim SH, Rim TH, Lee SK (2016) Incremental prognostic value of ADC Histogram Analysis over MGMT promoter methylation status in patients with Glioblastoma. Radiology 281(1):175–184. https://doi.org/10.1148/radiol.2016151913. (PMID: 10.1148/radiol.201615191327120357) Drabycz S, Roldan G, de Robles P, Adler D, McIntyre JB, Magliocco AM, Cairncross JG, Mitchell JR (2010) An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. NeuroImage 49(2):1398–1405. https://doi.org/10.1016/j.neuroimage.2009.09.049. (PMID: 10.1016/j.neuroimage.2009.09.04919796694) Ellingson BM, Cloughesy TF, Pope WB, Zaw TM, Phillips H, Lalezari S, Nghiemphu PL, Ibrahim H, Naeini KM, Harris RJ, Lai A (2012) Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. NeuroImage 59(2):908–916. https://doi.org/10.1016/j.neuroimage.2011.09.076. (PMID: 10.1016/j.neuroimage.2011.09.07622001163) Gatto L, Franceschi E, Tosoni A, Di Nunno V, Tonon C, Lodi R, Agati R, Bartolini S, Brandes AA (2022) Beyond Imaging and Genetic Signature in Glioblastoma: radiogenomic holistic Approach in Neuro-Oncology. Biomedicines 10(12). https://doi.org/10.3390/biomedicines10123205. Gihr GA, Horvath-Rizea D, Kohlhof-Meinecke P, Ganslandt O, Henkes H, Richter C, Hoffmann KT, Surov A, Schob S (2018) Histogram Profiling of Postcontrast T1-Weighted MRI gives Valuable insights into Tumor Biology and enables prediction of growth kinetics and prognosis in Meningiomas. Transl Oncol 11(4):957–961. https://doi.org/10.1016/j.tranon.2018.05.009. (PMID: 10.1016/j.tranon.2018.05.009299093656008484) Han Y, Yan LF, Wang XB, Sun YZ, Zhang X, Liu ZC, Nan HY, Hu YC, Yang Y, Zhang J, Yu Y, Sun Q, Tian Q, Hu B, Xiao G, Wang W, Cui GB (2018) Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis. BMC Cancer 18(1):215. https://doi.org/10.1186/s12885-018-4114-2. (PMID: 10.1186/s12885-018-4114-2294670125822523) He W, Li X, Hua J, Liao S, Guo L, Xiao X, Liu X, Zhou J, Wang W, Xu Y, Wu Y (2021) Noninvasive Assessment of O(6)-Methylguanine-DNA methyltransferase promoter methylation status in World Health Organization Grade II-IV Glioma using Histogram Analysis of Inflow-based vascular-space-occupancy combined with structural magnetic resonance imaging. J Magn Reson Imaging 54(1):227–236. https://doi.org/10.1002/jmri.27514. (PMID: 10.1002/jmri.2751433590929) Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. https://doi.org/10.1056/NEJMoa043331. (PMID: 10.1056/NEJMoa04333115758010) Lapointe S, Perry A, Butowski NA (2018) Primary brain tumours in adults. Lancet 392(10145):432–446. https://doi.org/10.1016/S0140-6736(18)30990-5. (PMID: 10.1016/S0140-6736(18)30990-530060998) Liu X, Han T, Wang Y, Liu H, Huang X, Zhou J (2023) Differentiating angiomatous meningioma from atypical meningioma using histogram analysis of apparent diffusion coefficient maps. Quant Imaging Med Surg 13(7):4160–4170. https://doi.org/10.21037/qims-22-1224. (PMID: 10.21037/qims-22-12243745632010347304) Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106. (PMID: 10.1093/neuonc/noab106341850768328013) Lu J, Li X, Li H (2021) Perfusion parameters derived from MRI for preoperative prediction of IDH mutation and MGMT promoter methylation status in glioblastomas. Magn Reson Imaging 83:189–195. https://doi.org/10.1016/j.mri.2021.09.005. (PMID: 10.1016/j.mri.2021.09.00534506909) Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 17(Suppl 4):iv1–iv62. https://doi.org/10.1093/neuonc/nov189. (PMID: 10.1093/neuonc/nov189265112144623240) Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, Garcia-Lopez JL, Piquer J, Safont MJ, Balana C, Sanchez-Cespedes M, Garcia-Villanueva M, Arribas L, Esteller M (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10(15):4933–4938. https://doi.org/10.1158/1078-0432.CCR-04-0392. (PMID: 10.1158/1078-0432.CCR-04-039215297393) Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain, Radiation Oncology T, G, National Cancer Institute of Canada Clinical Trials G (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10 (5):459–466. https://doi.org/10.1016/S1470-2045(09)70025-7. Wang G, Zhou J (2023) The value of whole-volume apparent diffusion coefficient histogram analysis in preoperatively distinguishing intracranial solitary fibrous tumor and transitional meningioma. Front Oncol 13:1155162. https://doi.org/10.3389/fonc.2023.1155162. (PMID: 10.3389/fonc.2023.11551623726097810228830) Weller M, Tabatabai G, Kastner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bahr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Husing J, Reifenberger G, Wick W, Group DS (2015) MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified Temozolomide Rechallenge in Progressive Glioblastoma: the DIRECTOR trial. Clin Cancer Res 21(9):2057–2064. https://doi.org/10.1158/1078-0432.CCR-14-2737. (PMID: 10.1158/1078-0432.CCR-14-273725655102) Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Ruda R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18(3):170–186. https://doi.org/10.1038/s41571-020-00447-z. (PMID: 10.1038/s41571-020-00447-z33293629) Xi YB, Guo F, Xu ZL, Li C, Wei W, Tian P, Liu TT, Liu L, Chen G, Ye J, Cheng G, Cui LB, Zhang HJ, Qin W, Yin H (2018) Radiomics signature: a potential biomarker for the prediction of MGMT promoter methylation in glioblastoma. J Magn Reson Imaging 47(5):1380–1387. https://doi.org/10.1002/jmri.25860. (PMID: 10.1002/jmri.2586028926163) Xue C, Zhou Q, Zhang P, Zhang B, Sun Q, Li S, Deng J, Liu X, Zhou J (2023) MRI histogram analysis of tumor-infiltrating CD8 + T cell levels in patients with glioblastoma. Neuroimage Clin 37:103353. https://doi.org/10.1016/j.nicl.2023.103353. (PMID: 10.1016/j.nicl.2023.103353368127689958466) You SH, Choi SH, Kim TM, Park CK, Park SH, Won JK, Kim IH, Lee ST, Choi HJ, Yoo RE, Kang KM, Yun TJ, Kim JH, Sohn CH (2018) Differentiation of high-Grade from Low-Grade Astrocytoma: improvement in diagnostic accuracy and reliability of pharmacokinetic parameters from DCE MR Imaging by using arterial input functions obtained from DSC MR Imaging. Radiology 286(3):981–991. https://doi.org/10.1148/radiol.2017170764. (PMID: 10.1148/radiol.201717076429244617) |
| معلومات مُعتمدة: | 82071872; 82260341; 82260361; 82371914 National Natural Science Foundation of China; Z-2014-07-2101 2021 SKY Imaging Research Fund of China International Medical Exchange Foundation; 21YF5FA123; 21JR11RA105 Science and Technology Program of Gansu Province |
| فهرسة مساهمة: | Keywords: Glioblastoma; Histogram analysis; Magnetic resonance imaging; O(6)-methylguanine-DNA methyltransferase |
| المشرفين على المادة: | EC 1.1.1.41 (Isocitrate Dehydrogenase) EC 2.1.1.63 (O(6)-Methylguanine-DNA Methyltransferase) |
| تواريخ الأحداث: | Date Created: 20240621 Date Completed: 20240621 Latest Revision: 20240621 |
| رمز التحديث: | 20240622 |
| DOI: | 10.1007/s10143-024-02522-w |
| PMID: | 38907038 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1437-2320 |
|---|---|
| DOI: | 10.1007/s10143-024-02522-w |